Novel biological strategies to enhance the radiation therapeutic ratio

다국어 초록 (Multilingual Abstract)

Successful anticancer strategies require a differential response between tumor and normal tissue (i.e., a therapeutic ratio). In fact, improving the effectiveness of a cancer therapeutic is of no clinical value in the absence of a significant increase in the differential response between tumor and normal tissue. Although radiation dose escalation with the use of intensity modulated radiation therapy has permitted the maximum tolerable dose for most locally advanced cancers, improvements in tumor control without damaging normal adjacent tissues are needed. As a means of increasing the therapeutic ratio, several new approaches are under development. Drugs targeting signal transduction pathways in cancer progression and more recently, immunotherapeutics targeting specific immune cell subsets have entered the clinic with promising early results. Radiobiological research is underway to address pressing questions as to the dose per fraction, irradiated tumor volume and time sequence of the drug administration.
To exploit these exciting novel strategies, a better understanding is needed of the cellular and molecular pathways responsible for both cancer and normal tissue and organ response, including the role of radiation-induced accelerated senescence. This review will highlight the current understanding of promising biologically targeted therapies to enhance the radiation therapeutic ratio.

참고문헌 (Reference)

1 Hayman TJ, "Translation initiation factor eIF4E is a target for tumor cell radiosensitization" 72 : 2362-2372, 2012

2 Wang Y, "Total body irradiation selectively induces murine hematopoietic stem cell senescence" 107 : 358-366, 2006

3 Jenrow KA, "Time-dependent inhibition of pan-inflammatory cytokines mitigates radiation-induced skin injury in mice" 182 : 316-321, 2014

4 Lawrence J, "The role of the mammalian target of rapamycin (mTOR) in pulmonary fibrosis" 19 : E778-, 2018

5 Prevo R, "The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy" 13 : 1072-1081, 2012

6 Sorensen CS, "The cellcycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair" 7 : 195-201, 2005

7 Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy" 12 : 252-264, 2012

8 Hayman TJ, "The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells" 20 : 110-119, 2014

9 Albert JM, "Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer" 5 : 1183-1189, 2006

10 Sarcar B, "Targeting radiationinduced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines" 10 : 2405-2414, 2011

11 Bouquet F, "TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo" 17 : 6754-6765, 2011

12 Vanpouille-Box C, "TGFβ is a master regulator of radiation therapy-induced antitumor immunity" 75 : 2232-2242, 2015

13 Formenti SC, "Systemic effects of local radiotherapy" 10 : 718-726, 2009

14 Origanti S, "Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells" 32 : 577-588, 2013

15 Lew YS, "Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor" 62 : 4202-4205, 2002

16 Hirai H, "Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents" 8 : 2992-3000, 2009

17 Shiotani B, "Single-stranded DNA orchestrates an ATMto-ATR switch at DNA breaks" 33 : 547-558, 2009

18 Engelke CG, "Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776" 19 : 4412-4421, 2013

19 Kim JH, "Senolytics mitigate radiation-induced normal tissue damage" 2018

20 Jenrow KA, "Selective inhibition of microglia-mediated neuroinflammation mitigates radiation-induced cognitive impairment" 179 : 549-556, 2013

21 Tang L, "Role of metabolism in cancer cell radioresistance and radiosensitization methods" 37 : 87-, 2018

22 Anscher MS, "Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy" 56 : 988-995, 2003

23 Zannella VE, "Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response" 19 : 6741-6750, 2013

24 Kelly CJ, "Regulation of O2consumption by the PI3K and mTOR pathways contributes to tumor hypoxia" 111 : 72-80, 2014

25 Olcina MM, "Reducing radiation-induced gastrointestinal toxicity: the role of the PHD/HIF axis" 126 : 3708-3715, 2016

26 Citrin DE, "Recent Developments in Radiotherapy" 377 : 1065-1075, 2017

27 Khosravi R, "Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage" 96 : 14973-14977, 1999

28 NRG Oncology, "Randomized phase II trial of concurrent chemoradiotherapy +/- metformin HCL in locally advanced NSCLC" NRG Oncology 2016

29 구태률, "Radiotherapy and immune checkpoint blockades:a snapshot in 2016" 대한방사선종양학회 34 (34): 250-259, 2016

30 Tao Y, "Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints" 8 : 1196-1205, 2009

31 Ushijima H, "Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions" 56 : 663-668, 2015

32 Day RM, "Radiation-induced accelerated senescence: a fate worse than death?" 13 : 2011-2012, 2014

33 Morris JC, "Phase I study of GC1008(fresolimumab): a human anti-transforming growth factorbeta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma" 9 : e90353-, 2014

34 Taniguchi CM, "PHD inhibition mitigates and protects against radiation-induced gastrointestinal toxicity via HIF2" 6 : 236-264, 2014

35 Kim KW, "NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma" 5 : 293-302, 2014

36 Giaccia AJ, "Molecular radiobiology: the state of the art" 32 : 2871-2878, 2014

37 Kalender A, "Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner" 11 : 390-401, 2010

38 Song CW, "Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells" 2 : 362-, 2012

39 Storozhuk Y, "Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK" 108 : 2021-2032, 2013

40 Jae Ho Kim, "Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials" 대한방사선종양학회 32 (32): 103-115, 2014

41 Schaue D, "Maximizing tumor immunity with fractionated radiation" 83 : 1306-1310, 2012

42 Qian BZ, "Macrophage diversity enhances tumor progression and metastasis" 141 : 39-51, 2010

43 Brown, SL, "MRI-tracked tumor vasculature changes in the hours after single fraction irradiation" 183 : 713-721, 2015

44 Suzuki M, "MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis" 10 : 491-500, 2017

45 Bridges KA, "MK-1775, a novel Wee1kinase inhibitor, radiosensitizes p53-defective human tumor cells" 17 : 5638-5648, 2011

46 Ehrhart EJ, "Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation" 11 : 991-1002, 1997

47 Wang Y, "Ionizing radiation-induced endothelial cell senescence and cardiovascular diseases" 186 : 153-161, 2016

48 Richardson RB, "Ionizing radiation and aging: rejuvenating an old idea" 1 : 887-902, 2009

49 Eshleman JS, "Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy" 62 : 7291-7297, 2002

50 Panganiban RA, "Inhibition of IGF-1R prevents ionizing radiation-induced primary endothelial cell senescence" 8 : e78589-, 2013

51 Pan J, "Inhibition of Bcl-2/xl with ABT-263selectively kills senescent type II pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice" 99 : 353-361, 2017

52 Morgan MA, "Improving the efficacy of chemoradiation with targeted agents" 4 : 280-291, 2014

53 Old LJ, "Immunology of experimental tumors" 15 : 167-186, 1964

54 Postow MA, "Immunologic correlates of the abscopal effect in a patient with melanoma" 366 : 925-931, 2012

55 Brahmer JR, "Immune checkpoint inhibitors:making immunotherapy a reality for the treatment of lung cancer" 1 : 85-91, 2013

56 Fuhrmann-Stroissnigg H, "Identification of HSP90 inhibitors as a novel class of senolytics" 8 : 422-, 2017

57 Liang H, "Host STING-dependent MDSC mobilization drives extrinsic radiation resistance" 8 : 1736-, 2017

58 Tsushima H, "High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression" 110 : 375-382, 1996

59 Dewan MZ, "Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody" 15 : 5379-5388, 2009

60 Formenti SC, "Focal irradiation and systemic TGFβ Blockade in metastatic breast cancer" 24 : 2493-2504, 2018

61 Mauceri HJ, "Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer" 27 : 1625-1629, 2012

62 Shinohara ET, "Enhanced radiation damage of tumor vasculature by mTOR inhibitors" 24 : 5414-5422, 2005

63 Chang L, "Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy" 33 : 469-496, 2014

64 Acharya MM, "Elimination of microglia improves cognitive function following cranial irradiation" 6 : 31545-, 2016

65 Nagata Y, "Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status" 37 : 1001-1010, 2010

66 Jaklevic B, "Contribution of growth and cell cycle checkpoints to radiation survival in Drosophila" 174 : 1963-1972, 2006

67 Nassim R, "Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment" 8 : e65257-, 2013

68 Son CH, "Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer" 92 : 390-398, 2015

69 Cannarile MA, "Colony-stimulating factor 1 receptor (CSF1R)inhibitors in cancer therapy" 5 : 53-, 2017

70 Bartek J, "Chk1 and Chk2 kinases in checkpoint control and cancer" 3 : 421-429, 2003

71 Kirkland JL, "Cellular senescence: a translational perspective" 21 : 21-28, 2017

72 Rizvi NA, "Cancer immunology:mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer" 348 : 124-128, 2015

73 Kim JH, "Arsenic trioxide enhances radiation response of 9L glioma in the rat brain" 160 : 662-666, 2003

74 Old LJ, "Antigenic modulation:loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro" 127 : 523-539, 1968

75 Callahan MK, "Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy" 37 : 473-484, 2010

76 Golden EB, "An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer" 1 : 365-372, 2013

77 Qiu Z, "ATR/CHK1 inhibitors and cancer therapy" 126 : 450-464, 2018

78 Sharlow ER, "A small molecule screen exposes mTOR signaling pathway involvement in radiation-induced apoptosis" 11 : 1428-1437, 2016

79 McBride WH, "A perspective on the impact of radiation therapy on the immune rheostat" 90 : 20170272-, 2017